Previous 10 |
Enhabit appears to be significantly undervalued compared to peers in the same line of business. On an absolute basis, Enhabit looks cheap compared to its future cash flows. As a recent spinoff, Enhabit has come under non-fundamental selling pressure. Thesis Enhabit, ...
News, Short Squeeze, Breakout and More Instantly...
Glass Lewis Concludes That Support is Merited for AREX Nominees to Add “Fresh Perspectives and Relevant Expertise” Two Leading Independent Proxy Advisory Firms Recognize That Boardroom Change is Urgently Needed at Enhabit AREX Capital Management, LP (together...
Enhabit, Inc. (NYSE: EHAB) (“Enhabit” or the “Company”), a leading home health and hospice provider, today announced certain unaudited preliminary results for the second quarter ended June 30, 2024. The Company plans to report actual second quarter 2024 financial resul...
ISS Concludes Support Is Warranted for AREX Nominees to Add Beneficial Industry-Specific Expertise and “Oversight Over the Company's Financial Reporting and Shareholder Communications” ISS Recognizes “The Most Apparent Needs for the Board Are Additional Expertise ...